Assessment of prognostic markers in benign and malignant melanocytic tumours

Cutaneous melanoma is a malignant tumour that arises from pigmented skin cells – melanocytes, represents the most rapidly increasing cancer worldwide which is causing significant public health problem. During the past decade a significant progress has been made in the understanding of genesis and progression of melanocytic lesions. However treatment of malignant melanomas is in a majority of cases limited to surgical excision of the primary tumours or metastases. In advanced metastatic disease there are few treatment options.

The present thesis reviews current knowledge on epidemiology, ethiology, pathology and treatment options of the benign and malignant melanocytic tumours and concentrates on the analysis of several molecules that are thought to play a role in the processes of cell growth, apoptosis, division, motility and adhesion as well as regulation of cytoskeletal components, protein phosphorylation, cell-cycle and cell survival. Archival material from fine needle aspirates as well as formalin-fixed tumour tissue was used in the study. Primary benign and malignant melanocytic tumours as well as metastatic melanomas were included in the study. The expression of the following proteins in malignant and benign melanocytic tumours was analyzed: S100, CD40, CD44, Bcl-2, Ki-67, COX-2 and HSP90. The expression patterns of the proteins were correlated to pathomorphological properties of the tumours as well as clinical parameters. Moreover, a presence of the BRAF gene mutation V600 has been analyzed in metastases from malignant melanomas.

We found that melanocytic tumours are heterogeneous in respect to expression of the analyzed proteins as well as mutational status. Analysis of biomarkers and genetic aberrations might therefore be of importance for predicting the biological behaviour of the tumours. The results of the study are discussed in the light of eventual prognostic, diagnostic and therapeutic application of the analyzed proteins and mutational status.

List of scientific papers

I. Sviatoha V, Rundgren Å, Tani E, Kleina R, Skoog L. Expression of CD40, CD44, Bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma. Cytopathology. 2002 Feb;13(1):11-12.
https://doi.org/10.1046/j.1365-2303.2002.00376.x

II. Sviatoha V, Kleina R, Tani E, Skoog L. Expression of the CD117, COX-2 and HSP90 antigens and cell proliferation in fine-needle aspirated cells from metastatic melanomas. Anticancer Research. 2009 Nov;29(11):4345-52.
https://pubmed.ncbi.nlm.nih.gov/20032377

III. Sviatoha V, Tani E, Kleina R, Sperga M, Skoog L. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours. Melanoma Research. 2010 Apr;20(2):118-25.
https://doi.org/10.1097/CMR.0b013e3283350554

IV. Sviatoha V, Tani E, Ghaderi M, Kleina R, Skoog L. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas. Anticancer Research. 2010 Sep;30(9):3267-72.
https://pubmed.ncbi.nlm.nih.gov/20944096